Cargando…
Natalizumab for GVHD: too little or too late?
Autores principales: | Quann, Kevin, Sacirbegovic, Faruk, Shlomchik, Warren D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505719/ https://www.ncbi.nlm.nih.gov/pubmed/37698891 http://dx.doi.org/10.1182/bloodadvances.2023010486 |
Ejemplares similares
-
Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023) -
More evidence for low-dose IL-2 for chronic GVHD in children
por: Levine, John E.
Publicado: (2023) -
COVID-19: too little, too late?
por: The Lancet
Publicado: (2020) -
The Opioid Crisis in America: Too much, too little, too late
por: Koenig, Kristi L.
Publicado: (2018) -
Too little too late: Waiting for TB to come
por: Kawamura, L. Masae
Publicado: (2018)